International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease
- PMID: 37589025
- PMCID: PMC10425321
- DOI: 10.1007/s43657-022-00068-9
International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer's Disease
Abstract
Alzheimer's disease (AD) is the main cause of dementia, with its diagnosis and management remaining challenging. Amyloid positron emission tomography (PET) has become increasingly important in medical practice for patients with AD. To integrate and update previous guidelines in the field, a task group of experts of several disciplines from multiple countries was assembled, and they revised and approved the content related to the application of amyloid PET in the medical settings of cognitively impaired individuals, focusing on clinical scenarios, patient preparation, administered activities, as well as image acquisition, processing, interpretation and reporting. In addition, expert opinions, practices, and protocols of prominent research institutions performing research on amyloid PET of dementia are integrated. With the increasing availability of amyloid PET imaging, a complete and standard pipeline for the entire examination process is essential for clinical practice. This international consensus and practice guideline will help to promote proper clinical use of amyloid PET imaging in patients with AD.
Keywords: Alzheimer’s disease; Amyloid; Brain imaging; Expert consensus; Positron emission tomography (PET).
© The Author(s) 2022.
Conflict of interest statement
Conflicts of InterestThe authors declare that they have no conflict of interest.
Figures


Similar articles
-
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer's disease.Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):895-904. doi: 10.1007/s00259-021-05673-w. Epub 2022 Jan 3. Eur J Nucl Med Mol Imaging. 2022. PMID: 34978595 Free PMC article.
-
Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.Can J Neurol Sci. 2016 Jul;43(4):503-12. doi: 10.1017/cjn.2015.401. Epub 2016 Feb 26. Can J Neurol Sci. 2016. PMID: 26916179
-
Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary.Alzheimers Dement. 2016 Apr;12(4):510-5. doi: 10.1016/j.jalz.2016.03.002. Alzheimers Dement. 2016. PMID: 27103054
-
Clinical Amyloid Imaging.Semin Nucl Med. 2017 Jan;47(1):31-43. doi: 10.1053/j.semnuclmed.2016.09.005. Epub 2016 Nov 24. Semin Nucl Med. 2017. PMID: 27987555 Review.
-
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.J Nucl Med. 2013 Mar;54(3):476-90. doi: 10.2967/jnumed.113.120618. Epub 2013 Jan 28. J Nucl Med. 2013. PMID: 23359661 Review.
Cited by
-
Impaired glymphatic function as a biomarker for subjective cognitive decline: An exploratory dual cohort study.Alzheimers Dement. 2024 Sep;20(9):6542-6555. doi: 10.1002/alz.14149. Epub 2024 Aug 6. Alzheimers Dement. 2024. PMID: 39107995 Free PMC article.
-
Diagnostic performance of artificial intelligence-assisted PET imaging for Parkinson's disease: a systematic review and meta-analysis.NPJ Digit Med. 2024 Jan 22;7(1):17. doi: 10.1038/s41746-024-01012-z. NPJ Digit Med. 2024. PMID: 38253738 Free PMC article.
-
Improved interpretation of 18F-florzolotau PET in progressive supranuclear palsy using a normalization-free deep-learning classifier.iScience. 2023 Jul 20;26(8):107426. doi: 10.1016/j.isci.2023.107426. eCollection 2023 Aug 18. iScience. 2023. PMID: 37564702 Free PMC article.
-
Positron Emission Tomography Imaging of Synaptic Dysfunction in Parkinson's Disease.Neurosci Bull. 2024 Jun;40(6):743-758. doi: 10.1007/s12264-024-01188-0. Epub 2024 Mar 14. Neurosci Bull. 2024. PMID: 38483697 Free PMC article. Review.
-
Medical image Generative Pre-Trained Transformer (MI-GPT): future direction for precision medicine.Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):332-335. doi: 10.1007/s00259-023-06450-7. Eur J Nucl Med Mol Imaging. 2024. PMID: 37803245 No abstract available.
References
-
- Akamatsu G, Ikari Y, Ohnishi A, Matsumoto K, Nishida H, Yamamoto Y, et al. Voxel-based statistical analysis and quantification of amyloid PET in the Japanese Alzheimer's disease neuroimaging initiative (J-ADNI) multi-center study. EJNMMI Res. 2019;9(1):91. doi: 10.1186/s13550-019-0561-2. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources